Study summary

The main objective for this study is to assess the efficacy and dose-response relationship of ASP1707 in reduction of endometriosis associated pelvic pain. The secondary objectives are to assess the safety, tolerability, Pharmacokinetics of ASP1707, dose response relationship of ASP1707 in reduction of E2 (Estradiol), 24-week efficacy of ASP1707 in reduction of endometriosis associated pain and 24-week safety and tolerability of ASP1707.

Additional Study Details

Phase
2
Product
N/A
Product
ASP1707
Placebo
Leuprorelin acetate
Type
Interventional
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment number
912
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Plain Language Summary
Available Language(s): English

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A study to assess the effectiveness and safety of different doses of ASP1707 compared to placebo for endometriosis associated pelvic pain? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site: 1717
    Zaporizhzhya, Ukraine
    Completed
    Site: 2004
    Tokyo, Japan, 101 0062
    Completed
    Site: 2031
    Kumamoto, Japan, 861 8520
    Completed
    Site: 2014
    Tokyo, Japan, 113 8431
    Completed
    Site: 1703
    Targu Mures, Ukraine
    Completed
    Site: 1406
    Pecs, Hungary
    Completed
    Site: 2035
    Kanagawa, Japan
    Completed
    Site: 2001
    Sapporo, Japan, 060 0031
    Completed
    Site: 2015
    Kanagawa, Japan, 213 8507
    Completed
    Site: 2024
    Kawasaki, Japan, 212 0058
    Completed
    Site: 1602
    Bucharest, Romania, 11475
    Completed
    Site: 1104
    Sofia, Bulgaria, 1000
    Withdrawn
    Site: 1704
    Brasov, Ukraine
    Completed
    Site: 1102
    Sofia, Bulgaria
    Withdrawn
    Site: 1801
    Edinburgh, United Kingdom, EH16 4TJ
    Completed
    Site: 2033
    Kochi, Japan, 783 8505
    Completed
    Site: 2009
    Tokyo, Japan, 113 8603
    Completed
    Site: 1702
    Bucuresti, Ukraine
    Completed
    Site: 1701
    Bucuresti, Ukraine
    Completed
    Site: 2038
    Nagano, Japan
    Completed
    Site: 1512
    Gdansk, Poland
    Withdrawn
    Site: 1527
    Krakow, Poland
    Withdrawn
    Site: 1308
    Hamburg, Germany
    Completed
    Site: 1508
    Lublin, Poland, 20-333
    Withdrawn
    Site: 2019
    Sendai, Japan
    Withdrawn
    Site: 1109
    Burgas, Bulgaria
    Completed
    Site: 1304
    Dresden, Germany
    Completed
    Site: 2017
    Chiba, Japan, 299 0111
    Completed
    Site: 1106
    Sofia, Bulgaria, 1504
    Completed
    Site: 1806
    Southampton, United Kingdom, SO16 5YA
    Completed
    Site: 2032
    Kagoshima, Japan
    Completed
    Site: 1403
    Szekszard, Hungary, 7100
    Completed
    Site: 1401
    Budapest, Hungary, 1135
    Withdrawn
    Site: 1305
    Frankfurt, Germany
    Completed
    Site: 2036
    Nagano, Japan
    Completed
    Site: 1302
    Erlangen, Germany
    Completed
    Site: 2020
    Tokyo, Japan, 107 0052
    Withdrawn
    Site: 1310
    Essen, Germany
    Completed
    Site: 1504
    Katowice, Poland, 40-724
    Completed
    Site: 1606
    Bucuresti, Romania
    Completed
    Site: 1716
    Donetsk, Ukraine
    Completed
    Site: 1003
    Gent, Belgium, 9000
    Withdrawn
    Site: 1404
    Budapest, Hungary
    Completed
    Site: 1804
    Norwich, United Kingdom, NR47UY
    Completed
    Site: 1103
    Stara Zagora, Bulgaria, 6000
    Completed
    Site: 2040
    Hyogo, Japan
    Completed
    Site: 2037
    Nagano, Japan
    Completed
    Site: 1306
    Luebeck, Germany
    Completed
    Site: 1311
    Karlsruhe, Germany
    Completed
    Site: 2005
    Fujisawa, Japan, 252 0804
    Completed
    Site: 2034
    Hyogo, Japan, 666 0195
    Completed
    Site: 1509
    Warsaw, Poland
    Completed
    Site: 1407
    Budapest, Hungary
    Completed
    Site: 2013
    Kawagoe, Japan, 350-8550
    Completed
    Site: 2027
    Sapporo, Japan, 060 0001
    Completed
    Site: 1390
    Berlin, Germany
    Withdrawn
    Site: 1004
    Brussels, Belgium
    Completed
    Site: 1807
    London, United Kingdom, SE5 9RS
    Completed
    Site: 2029
    Kawasaki, Japan, 210 0024
    Completed
    Site: 2025
    Tokyo, Japan, 157 0061
    Completed
    Site: 1713
    Donetsk, Ukraine
    Completed
    Site: 2016
    Tokyo, Japan
    Completed
    Site: 1005
    Liege, Belgium, 4000
    Completed
    Site: 1708
    Kyiv, Ukraine
    Completed
    Site: 2003
    Tokyo, Japan, 1130033
    Completed
    Site: 2010
    Kurashiki, Japan, 710 0824
    Completed
    Site: 1808
    Sheffield, United Kingdom, S10 2SF
    Completed
    Site: 2007
    Nagasaki, Japan, 850 0003
    Completed
    Site: 1607
    Bucaresti, Romania
    Withdrawn
    Site: 1506
    Warsaw, Poland
    Completed
    Site: 2006
    Kyoto, Japan, 602 8566
    Withdrawn
    Site: 1526
    Piaseczno, Poland
    Completed
    Site: 1507
    Lublin, Poland, 20-632
    Completed
    Site: 1422
    Kecskemet, Bacs-Kiskun Megye, Hungary, 6000
    Completed
    Site: 1501
    Bialystok, Poland, 15-464
    Completed
    Site: 1107
    Sofia, Bulgaria, 1330
    Withdrawn
    Site: 1605
    Bucharest, Romania, 20762
    Completed
    Site: 2018
    Aomori, Japan, 036 8203
    Completed
    Site: 1001
    Leuven, Belgium, 3000
    Completed
    Site: 1408
    Debrecen, Hungary, 4012
    Completed
    Site: 1002
    Genk, Belgium, 3600
    Completed
    Site: 2011
    Nara, Japan, 631 0805
    Withdrawn
    Site: 1405
    Szentes, Hungary
    Completed
    Site: 1604
    Brasov, Romania
    Completed
    Site: 1603
    Targu Mures, Romania
    Completed
    Site: 2012
    Yokohama, Japan, 225 0024
    Completed
    Site: 2039
    Hyogo, Japan
    Completed
    Site: 1525
    Warzawa, Poland
    Completed
    Site: 1006
    Bruxelles, Belgium, 1200
    Completed
    Site: 1105
    Plovdiv, Bulgaria
    Completed
    Site: 1705
    Bucuresti, Ukraine
    Completed
    Site: 1601
    Bucuresti, Romania
    Completed
    Site: 2030
    Sapporo, Japan, 060 0061
    Completed
    Site: 1402
    Szekesfehervar, Hungary
    Completed
    Site: 1505
    Bialystok, Poland
    Withdrawn
    Site: 1802
    Oxford, United Kingdom
    Completed
    Site: 1707
    Bucuresti, Ukraine
    Withdrawn
    Site: 1706
    Bucuresti, Ukraine
    Completed
    Site: 2028
    Tokyo, Japan, 141 0022
    Completed
    Site: 2002
    Nagaoka, Japan, 940 2085
    Completed
    Site: 1502
    Warszawa, Poland, 02-066

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?